A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Clinical Study of Chiauranib Capsule in Patients With Progressed or Relapsed Small-cell Lung Cancer After 2 Lines Chemotherapy (CHIS)
Latest Information Update: 11 Dec 2024
At a glance
- Drugs Ibcasertib (Primary)
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CHIS
- Sponsors Chipscreen Biosciences
Most Recent Events
- 02 Dec 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 01 Nov 2024 Status changed from recruiting to completed, according to a Chipscreen Biosciences media release.
- 15 Jul 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Dec 2024.